Valsartan
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-22-D-0144
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
This procurement notice announces the award of a national contract, identified as SPE2D2-22-D-0144, for the supply of Valsartan. The contract is managed by DLA Troop Support, a federal office responsible for providing critical supplies to military and government entities. The primary place of performance for this contract is Brookhaven, New York, indicating that manufacturing, distribution, or fulfillment activities related to Valsartan will be centered in this location.
The scope of this contract encompasses the manufacturing and supply of Valsartan, a pharmaceutical preparation, as classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). The intent of this procurement is to ensure a reliable and consistent supply of Valsartan, supporting the medical and pharmaceutical needs of federal agencies and potentially military personnel.
Key requirements for this contract likely include adherence to stringent pharmaceutical manufacturing standards, compliance with all applicable federal regulations, and the ability to deliver Valsartan in accordance with the specifications and quantities outlined by DLA Troop Support. Contractors are expected to maintain high quality assurance protocols and demonstrate capacity for timely and efficient fulfillment to meet the ongoing needs of the government.
The contracting activity is overseen by DLA Troop Support, with Christopher Newman and Jason Wray serving as the primary and secondary points of contact, respectively. Interested parties or current contractors may reach out to Mr. Newman at [email protected] or 215-737-2905, and Mr. Wray at [email protected] or 215-737-0614, for further information or contract administration matters.
This award notice is currently active and was posted on September 24, 2025. Additional details, including attachments related to the contract, can be accessed via the official SAM.gov opportunity page at https://sam.gov/opp/df1369519f7f423096ce593d47f63b36/view.
Contractors evaluating this opportunity should note that it is a national-level contract for a critical pharmaceutical product, requiring robust manufacturing capabilities, regulatory compliance, and a proven track record in supplying pharmaceutical preparations to federal entities. The contract’s focus on Valsartan positions it as a specialized opportunity for firms with expertise in cardiovascular medications and large-scale pharmaceutical supply chains.